WARNINGS
Included as part of the PRECAUTIONS section.
PRECAUTIONS
Skeletal Muscle Effects
Cases of myopathy and rhabdomyolysis with acute renal failure secondary to myoglobinuria have been reported with HMG-CoA reductase inhibitors , including Rosuvastatina Aurobindo. These risks can occur at any dose level, but are increased at the highest dose (40 mg).
Rosuvastatina Aurobindo should be prescribed with caution in patients with predisposing factors for myopathy (e.g., age ≥ 65 years, inadequately treated hypothyroidism, renal impairment).
The risk of myopathy during treatment with Rosuvastatina Aurobindo may be increased with concurrent administration of some other lipid-lowering therapies (fibrates or niacin), gemfibrozil, cyclosporine, atazanavir/ritonavir, lopinavir/ritonavir, or simeprevir. Cases of myopathy, including rhabdomyolysis, have been reported with HMG-CoA reductase inhibitors, including rosuvastatin, coadministered with colchicine, and caution should be exercised when prescribing Rosuvastatina Aurobindo with colchicine.
Rosuvastatina Aurobindo therapy should be discontinued if markedly elevated creatine kinase levels occur or myopathy is diagnosed or suspected. Rosuvastatina Aurobindo therapy should also be temporarily withheld in any patient with an acute, serious condition suggestive of myopathy or predisposing to the development of renal failure secondary to rhabdomyolysis (e.g., sepsis, hypotension, dehydration, major surgery, trauma, severe metabolic, endocrine, and electrolyte disorders, or uncontrolled seizures).
There have been rare reports of immune-mediated necrotizing myopathy (IMNM), an autoimmune myopathy, associated with statin use. IMNM is characterized by: proximal muscle weakness and elevated serum creatine kinase, which persist despite discontinuation of statin treatment; muscle biopsy showing necrotizing myopathy without significant inflammation; improvement with immunosuppressive agents.
All patients should be advised to promptly report to their physician unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever or if muscle signs and symptoms persist after discontinuing Rosuvastatina Aurobindo.
Liver Enzyme Abnormalities
It is recommended that liver enzyme tests be performed before the initiation of Rosuvastatina Aurobindo, and if signs or symptoms of liver injury occur.
Increases in serum transaminases [AST (SGOT) or ALT (SGPT)] have been reported with HMGCoA reductase inhibitors, including Rosuvastatina Aurobindo. In most cases, the elevations were transient and resolved or improved on continued therapy or after a brief interruption in therapy. There were two cases of jaundice, for which a relationship to Rosuvastatina Aurobindo therapy could not be determined, which resolved after discontinuation of therapy. There were no cases of liver failure or irreversible liver disease in these trials.
In a pooled analysis of placebo-controlled trials, increases in serum transaminases to > 3 times the upper limit of normal occurred in 1.1% of patients taking Rosuvastatina Aurobindo versus 0.5% of patients treated with placebo.
There have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins, including rosuvastatin. If serious liver injury with clinical symptoms and/or hyperbilirubinemia or jaundice occurs during treatment with Rosuvastatina Aurobindo, promptly interrupt therapy. If an alternate etiology is not found, do not restart Rosuvastatina Aurobindo.
Rosuvastatina Aurobindo should be used with caution in patients who consume substantial quantities of alcohol and/or have a history of chronic liver disease. Active liver disease, which may include unexplained persistent transaminase elevations, is a contraindication to the use of Rosuvastatina Aurobindo.
Concomitant Coumarin Anticoagulants
Caution should be exercised when anticoagulants are given in conjunction with Rosuvastatina Aurobindo because of its potentiation of the effect of coumarin-type anticoagulants in prolonging the prothrombin time/INR. In patients taking coumarin anticoagulants and Rosuvastatina Aurobindo concomitantly, INR should be determined before starting Rosuvastatina Aurobindo and frequently enough during early therapy to ensure that no significant alteration of INR occurs.
Proteinuria And Hematuria
In the Rosuvastatina Aurobindo clinical trial program, dipstick-positive proteinuria and microscopic hematuria were observed among Rosuvastatina Aurobindo treated patients. These findings were more frequent in patients taking Rosuvastatina Aurobindo 40 mg, when compared to lower doses of Rosuvastatina Aurobindo or comparator HMGCoA reductase inhibitors, though it was generally transient and was not associated with worsening renal function. Although the clinical significance of this finding is unknown, a dose reduction should be considered for patients on Rosuvastatina Aurobindo therapy with unexplained persistent proteinuria and/or hematuria during routine urinalysis testing.
Endocrine Effects
Increases in HbA1c and fasting serum glucose levels have been reported with HMGCoA reductase inhibitors, including Rosuvastatina Aurobindo. Based on clinical trial data with Rosuvastatina Aurobindo, in some instances these increases may exceed the threshold for the diagnosis of diabetes mellitus.
Although clinical studies have shown that Rosuvastatina Aurobindo alone does not reduce basal plasma cortisol concentration or impair adrenal reserve, caution should be exercised if Rosuvastatina Aurobindo is administered concomitantly with drugs that may decrease the levels or activity of endogenous steroid hormones such as ketoconazole, spironolactone, and cimetidine.
Patient Counseling Information
Advise the patient to read the FDA-approved patient labeling (PATIENT INFORMATION).
Patients should be instructed not to take 2 doses of Rosuvastatina Aurobindo within 12 hours of each other.
Skeletal Muscle Effects
Patients should be advised to report promptly unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever or if these muscle signs or symptoms persist after discontinuing Rosuvastatina Aurobindo.
Concomitant Use Of Antacids
When taking Rosuvastatina Aurobindo with an aluminum and magnesium hydroxide combination antacid, the antacid should be taken at least 2 hours after Rosuvastatina Aurobindo administration.
Embryofetal Toxicity
Advise females of reproductive potential of the risk to a fetus, to use effective contraception during treatment, and to inform their healthcare provider of a known or suspected pregnancy.
Lactation
Advise women not to breastfeed during treatment with Rosuvastatina Aurobindo.
Liver Enzymes
It is recommended that liver enzyme tests be performed before the initiation of Rosuvastatina Aurobindo and if signs or symptoms of liver injury occur. All patients treated with Rosuvastatina Aurobindo should be advised to promptly report any symptoms that may indicate liver injury, including fatigue, anorexia, right upper abdominal discomfort, dark urine or jaundice.
Nonclinical Toxicology
Carcinogenesis Mutagenesis, Impairment Of Fertility
In a 104-week carcinogenicity study in rats at dose levels of 2, 20, 60, or 80 mg/kg/day by oral gavage, the incidence of uterine stromal polyps was significantly increased in females at 80 mg/kg/day at systemic exposure 20 times the human exposure at 40 mg/day based on AUC. Increased incidence of polyps was not seen at lower doses.
In a 107-week carcinogenicity study in mice given 10, 60, or 200 mg/kg/day by oral gavage, an increased incidence of hepatocellular adenoma/carcinoma was observed at 200 mg/kg/day at systemic exposures 20 times the human exposure at 40 mg/day based on AUC. An increased incidence of hepatocellular tumors was not seen at lower doses.
Rosuvastatin was not mutagenic or clastogenic with or without metabolic activation in the Ames test with Salmonella typhimurium and Escherichia coli, the mouse lymphoma assay, and the chromosomal aberration assay in Chinese hamster lung cells. Rosuvastatin was negative in the in vivo mouse micronucleus test.
In rat fertility studies with oral gavage doses of 5, 15, 50 mg/kg/day, males were treated for 9 weeks prior to and throughout mating and females were treated 2 weeks prior to mating and throughout mating until gestation day 7. No adverse effect on fertility was observed at 50 mg/kg/day (systemic exposures up to 10 times the human exposure at 40 mg/day based on AUC). In testicles of dogs treated with rosuvastatin at 30 mg/kg/day for one month, spermatidic giant cells were seen. Spermatidic giant cells were observed in monkeys after 6month treatment at 30 mg/kg/day in addition to vacuolation of seminiferous tubular epithelium. Exposures in the dog were 20 times and in the monkey 10 times the human exposure at 40 mg/day based on body surface area. Similar findings have been seen with other drugs in this class.
Use In Specific Populations
Pregnancy
Risk Summary
Rosuvastatina Aurobindo is contraindicated for use in pregnant women since safety in pregnant women has not been established and there is no apparent benefit to therapy with Rosuvastatina Aurobindo during pregnancy. Because HMG-CoA reductase inhibitors decrease cholesterol synthesis and possibly the synthesis of other biologically active substances derived from cholesterol, Rosuvastatina Aurobindo may cause fetal harm when administered to pregnant women. Rosuvastatina Aurobindo should be discontinued as soon as pregnancy is recognized. Limited published data on the use of rosuvastatin are insufficient to determine a drug-associated risk of major congenital malformations or miscarriage. In animal reproduction studies, there were no adverse developmental effects with oral administration of rosuvastatin during organogenesis at systemic exposures equivalent to a maximum recommended human dose (MRHD) of 40 mg/day in rats or rabbits (based on AUC and body surface area, respectively). In rats and rabbits, decreased pup/fetal survival occurred at 12 times and equivalent, respectively, to the MRHD of 40 mg/day.
The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.
Data
Human Data
Limited published data on rosuvastatin have not shown an increased risk of major congenital malformations or miscarriage. Rare reports of congenital anomalies have been received following intrauterine exposure to other statins. In a review of approximately 100 prospectively followed pregnancies in women exposed to simvastatin or lovastatin, the incidences of congenital anomalies, spontaneous abortions, and fetal deaths/stillbirths did not exceed what would be expected in the general population. The number of cases is adequate to exclude a ≥ 3 to 4-fold increase in congenital anomalies over the background incidence. In 89% of the prospectively followed pregnancies, drug treatment was initiated prior to pregnancy and was discontinued at some point in the first trimester when pregnancy was identified.
Animal Data
Rosuvastatin crosses the placenta in rats and rabbits and is found in fetal tissue and amniotic fluid at 3% and 20%, respectively, of the maternal plasma concentration following a single 25 mg/kg oral gavage dose on gestation day 16 in rats. A higher fetal tissue distribution (25% maternal plasma concentration) was observed in rabbits after a single oral gavage dose of 1 mg/kg on gestation day 18.
Rosuvastatin administration did not indicate a teratogenic effect in rats at ≤ 25 mg/kg/day or in rabbits ≤ 3 mg/kg/day (doses equivalent to the MRHD of 40 mg/day based on AUC and body surface area, respectively).
In female rats given 5, 15 and 50 mg/kg/day before mating and continuing through to gestation day 7 resulted in decreased fetal body weight (female pups) and delayed ossification at 50 mg/kg/day (10 times the human exposure at the MRHD dose of 40 mg/day based on AUC).
In pregnant rats given 2, 10 and 50 mg/kg/day of rosuvastatin from gestation day 7 through lactation day 21 (weaning), decreased pup survival occurred at 50 mg/kg/day (dose equivalent to 12 times the MRHD of 40 mg/day based body surface area).
In pregnant rabbits given 0.3, 1, and 3 mg/kg/day of rosuvastatin from gestation day 6 to day 18, decreased fetal viability and maternal mortality was observed at 3 mg/kg/day (dose equivalent to the MRHD of 40 mg/day based on body surface area).
Lactation
Risk Summary
Rosuvastatin use is contraindicated during breastfeeding. Limited data indicate that Rosuvastatina Aurobindo is present in human milk. There is no available information on the effects of the drug on the breastfed infant or the effects of the drug on milk production. Because of the potential for serious adverse reactions in a breastfed infant, advise patients that breastfeeding is not recommended during treatment with Rosuvastatina Aurobindo.
Females And Males Of Reproductive Potential
Contraception
Rosuvastatina Aurobindo may cause fetal harm when administered to a pregnant woman. Advise females of reproductive potential to use effective contraception during treatment with Rosuvastatina Aurobindo.
Pediatric Use
In children and adolescents 8 to 17 years of age with heterozygous familial hypercholesterolemia, the safety and effectiveness of Rosuvastatina Aurobindo as an adjunct to diet to reduce total cholesterol, LDL-C, and ApoB levels when, after an adequate trial of diet therapy, LDL-C exceeds 190 mg/dL or when LDL-C exceeds 160 mg/dL and there is a positive family history of premature CVD or two or more other CVD risk factors, were established in one controlled trial and in one open-label, uncontrolled trial. The long-term efficacy of Rosuvastatina Aurobindo therapy initiated in childhood to reduce morbidity and mortality in adulthood has not been established.
The safety and effectiveness of Rosuvastatina Aurobindo in children and adolescents 10 to 17 years of age with heterozygous familial hypercholesterolemia were evaluated in a controlled clinical trial of 12 weeks duration followed by 40 weeks of open-label exposure. Patients treated with 5 mg, 10 mg, and 20 mg daily Rosuvastatina Aurobindo had an adverse experience profile generally similar to that of patients treated with placebo. There was no detectable effect of Rosuvastatina Aurobindo on growth, weight, BMI (body mass index), or sexual maturation in children and adolescents (10 to 17 years of age).
Rosuvastatina Aurobindo has not been studied in controlled clinical trials involving prepubertal patients or patients younger than 10 years of age with heterozygous familial hypercholesterolemia. However, the safety and effectiveness of Rosuvastatina Aurobindo were evaluated in a two year open-label uncontrolled trial that included children and adolescents 8 to 17 years of age with heterozygous familial hypercholesterolemia. The safety and efficacy of Rosuvastatina Aurobindo in lowering LDL-C appeared generally consistent with that observed for adult patients, despite limitations of the uncontrolled study design.
Children and adolescents 7 to 15 years of age with homozygous familial hypercholesterolemia were studied in a 6-week randomized, placebo-controlled, cross-over study with Rosuvastatina Aurobindo 20 mg once daily followed by 12 weeks of open-label treatment. In general, the safety profile in this trial was consistent with that of the previously established safety profile in adults.
Although not all adverse reactions identified in the adult population have been observed in clinical trials of children and adolescent patients, the same warnings and precautions for adults should be considered for children and adolescents. Adolescent females should be counseled on appropriate contraceptive methods while on Rosuvastatina Aurobindo therapy.
Geriatric Use
Of the 10,275 patients in clinical studies with Rosuvastatina Aurobindo, 3159 (31%) were 65 years and older, and 698 (6.8%) were 75 years and older. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.
Elderly patients are at higher risk of myopathy and Rosuvastatina Aurobindo should be prescribed with caution in the elderly.
Renal Impairment
Rosuvastatin exposure is not influenced by mild to moderate renal impairment (CLcr ≥ 30 mL/min/1.73 m²). Exposure to rosuvastatin is increased to a clinically significant extent in patients with severe renal impairment (CLcr < 30 mL/min/1.73 m²) who are not receiving hemodialysis and dose adjustment is required.
Hepatic Impairment
Rosuvastatina Aurobindo is contraindicated in patients with active liver disease, which may include unexplained persistent elevations of hepatic transaminase levels. Chronic alcohol liver disease is known to increase rosuvastatin exposure; Rosuvastatina Aurobindo should be used with caution in these patients.
Asian Patients
Pharmacokinetic studies have demonstrated an approximate 2-fold increase in median exposure to rosuvastatin in Asian subjects when compared with Caucasian controls. Rosuvastatina Aurobindo dosage should be adjusted in Asian patients.